- In late March 2026, Recursion Pharmaceuticals announced an expanded partnership with Citeline to deepen integration of real-world data into its AI-enabled ClinTech Platform, aiming to improve clinical trial design, site selection, and development decisions across its investigational portfolio.
- This move highlights how Recursion is trying to broaden the role of its AI-native platform beyond discovery into more predictive, patient-centered clinical execution, potentially making its technology more relevant to partners and pipeline programs alike.
- We’ll now examine how this enhanced Citeline collaboration, which strengthens Recursion’s AI-powered ClinTech capabilities, could influence the company’s broader investment narrative.
The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 20 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
Recursion Pharmaceuticals Investment Narrative Recap
To own Recursion, you need to believe its AI-first platform can translate into tangible clinical wins and durable partnerships before the cash runway tightens. The expanded Citeline collaboration may modestly support the key near term catalyst around advancing its REC‑4881 FAP program by improving trial design, but it does not change the central risks of heavy cash burn, dependence on partner milestones, and the possibility that early and mid stage programs fail to reach late stage development.
The Citeline news fits into a broader pattern of Recursion trying to pull more real world data into its stack, echoing the earlier HealthVerity agreement that opened access to data from over 340 million lives. Together, these moves could matter for upcoming clinical interactions, such as planned FDA discussions on REC‑4881’s potential registration path, by giving the company more tools to design feasible, patient centered studies and show regulators a clearer picture of real world need and benefit.
However, beneath this AI enabled progress, investors should still be aware of the very real risk that persistent cash burn and dilution could...
Read the full narrative on Recursion Pharmaceuticals (it's free!)
Recursion Pharmaceuticals' narrative projects $220.9 million revenue and $35.5 million earnings by 2028. This requires 50.7% yearly revenue growth and an earnings increase of about $684.6 million from -$649.1 million today.
Uncover how Recursion Pharmaceuticals' forecasts yield a $7.00 fair value, a 106% upside to its current price.
Exploring Other Perspectives
Some of the lowest ranked analysts were assuming Recursion’s revenue would reach only about US$102.1 million by 2028 with earnings of roughly US$16.6 million, which is a far more cautious view than consensus and highlights how opinions on cash burn and dilution risk can differ widely, especially as new announcements like the Citeline expansion potentially reshape both the upside case and the bear case you might consider.
Explore 6 other fair value estimates on Recursion Pharmaceuticals - why the stock might be worth over 3x more than the current price!
Reach Your Own Conclusion
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Recursion Pharmaceuticals research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
- Our free Recursion Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Recursion Pharmaceuticals' overall financial health at a glance.
Ready For A Different Approach?
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
- Find 64 companies with promising cash flow potential yet trading below their fair value.
- This technology could replace computers: discover 23 stocks that are working to make quantum computing a reality.
- The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com